Want to see HK:1167 full AI Analyst Report?
1167 Stock Chart & Stats
HK$8.06
HK$0.04(3.17%)
At close: 4:00 PM EST
HK$8.06
HK$0.04(3.17%)
Day’s Range― - ―
52-Week RangeHK$3.98 - HK$11.80
Previous CloseN/A
Volume546.60K
Average Volume (3M)7.94M
Market Cap
HK$3.68B
Enterprise ValueHK$4.11K
Total Cash (Recent Filing)HK$1.10B
Total Debt (Recent Filing)HK$165.24M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 28, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio3.18
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$723.51M
Bulls Say, Bears Say
Bulls Say
Oncology R&D FocusA focused clinical-stage small-molecule oncology pipeline provides durable strategic clarity. Concentrating resources on targeted therapies in high unmet-need indications supports scientific differentiation and potential high-value outcomes if candidates progress to later-stage trials or approvals.
Collaboration/licensing ModelA business model built on collaborations, licensing, milestones and royalties offers recurring non-dilutive funding levers. Durable partner payments can de-risk financing of R&D, smooth funding intermittency, and align incentives with third-party commercialization capabilities.
Manageable LeverageRelatively low debt versus equity provides balance-sheet flexibility typical for a clinical-stage biotech. Limited interest burden and available borrowing capacity help sustain R&D spend and navigate clinical timelines without excessive leverage-related constraints.
Bears Say
Sharp Revenue DeclineA ~74% year-over-year revenue drop reflects pronounced top-line volatility and weaker commercial or milestone conversion. Such a severe decline undermines predictable funding for development, complicates multi-year planning, and increases dependence on new deals or approvals to restore revenue.
Persistent Negative Cash FlowSustained negative operating and free cash flow, with rising cash burn in 2025, forces reliance on external capital or partner milestones. This structural funding pressure raises dilution risk, limits ability to consistently finance trials internally, and elevates execution risk until cash generation improves.
Cumulative Losses And Shrinking EquityOngoing net losses and declining shareholders' equity signal cumulative value erosion and negative ROE. This structural deterioration reduces financial resilience, can increase cost of capital, and constrains strategic flexibility if profitability and equity restoration are not achieved.
Jacobio Pharmaceuticals Group Co., Ltd. News
1167 FAQ
What was Jacobio Pharmaceuticals Group Co., Ltd.’s price range in the past 12 months?
Jacobio Pharmaceuticals Group Co., Ltd. lowest stock price was HK$3.98 and its highest was HK$11.80 in the past 12 months.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s market cap?
Jacobio Pharmaceuticals Group Co., Ltd.’s market cap is HK$3.68B.
When is Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date?
Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 20 days.
How were Jacobio Pharmaceuticals Group Co., Ltd.’s earnings last quarter?
Jacobio Pharmaceuticals Group Co., Ltd. released its earnings results on Mar 09, 2026. The company reported -HK$0.128 earnings per share for the quarter, missing the consensus estimate of -HK$0.012 by -HK$0.116.
Is Jacobio Pharmaceuticals Group Co., Ltd. overvalued?
According to Wall Street analysts Jacobio Pharmaceuticals Group Co., Ltd.’s price is currently Overvalued.
Does Jacobio Pharmaceuticals Group Co., Ltd. pay dividends?
Jacobio Pharmaceuticals Group Co., Ltd. does not currently pay dividends.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate?
Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate is 0.01.
How many shares outstanding does Jacobio Pharmaceuticals Group Co., Ltd. have?
Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding.
What happened to Jacobio Pharmaceuticals Group Co., Ltd.’s price movement after its last earnings report?
Jacobio Pharmaceuticals Group Co., Ltd. reported an EPS of -HK$0.128 in its last earnings report, missing expectations of -HK$0.012. Following the earnings report the stock price went down -0.325%.
Which hedge fund is a major shareholder of Jacobio Pharmaceuticals Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1167
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobio Pharmaceuticals Group Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
301.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.44%
Trailing 12-Months
Company Description
Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―